...
首页> 外文期刊>The journal of clinical investigation >Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation
【24h】

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

机译:人类C3突变揭示了致密沉积病发病机制,并提供了补体激活和调节的见解

获取原文

摘要

Dense deposit disease (DDD) is a severe renal disease characterized by accumulation of electron-dense material in the mesangium and glomerular basement membrane. Previously, DDD has been associated with deficiency of factor H (fH), a plasma regulator of the alternative pathway (AP) of complement activation, and studies in animal models have linked pathogenesis to the massive complement factor 3 (C3) activation caused by this deficiency. Here, we identified a unique DDD pedigree that associates disease with a mutation in the C3 gene. Mutant C3_(923ΔDG), which lacks 2 amino acids, could not be cleaved to C3b by the AP C3-convertase and was therefore the predominant circulating C3 protein in the patients. However, upon activation to C3b by proteases, or to C3(H_(2)O) by spontaneous thioester hydrolysis, C3_(923ΔDG) generated an active AP C3-convertase that was regulated normally by decay accelerating factor (DAF) but was resistant to decay by fH. Moreover, activated C3b_(923ΔDG) and C3(H_(2)O)_(923ΔDG) were resistant to proteolysis by factor I (fI) in the presence of fH, but were efficiently inactivated in the presence of membrane cofactor protein (MCP). These characteristics cause a fluid phase–restricted AP dysregulation in the patients that continuously activated and consumed C3 produced by the normal C3 allele. These findings expose structural requirements in C3 that are critical for recognition of the substrate C3 by the AP C3-convertase and for the regulatory activities of fH, DAF, and MCP, all of which have implications for therapeutic developments.
机译:致密沉积病(DDD)是一种严重的肾脏疾病,其特征是在系膜和肾小球基底膜中积累了电子致密物质。以前,DDD与补体激活的替代途径(AP)的血浆调节因子H(fH)缺乏相关,动物模型研究已将发病机制与由此引起的大量补体因子3(C3)激活联系起来。不足。在这里,我们确定了独特的DDD谱系,该谱系将疾病与C3基因的突变相关联。缺少2个氨基酸的突变体C3_(923ΔDG)无法被AP C3转化酶裂解为C3b,因此是患者体内主要的循环C3蛋白。但是,通过蛋白酶激活C3b或通过自发硫酯水解激活C3(H_(2)O)时,C3_(923ΔDG)产生了一种活性AP C3-转化酶,该酶通常受衰变加速因子(DAF)调控,但对由fH衰减。此外,活化的C3b_(923ΔDG)和C3(H_(2)O)_(923ΔDG)在fH存在下对因子I(fI)的蛋白水解有抵抗力,但在膜辅因子蛋白(MCP)存在下有效地失活。这些特征会导致持续激活并消耗正常C3等位基因产生的C3的患者受到液相限制的AP失调。这些发现揭示了C3中的结构要求,这些要求对于AP C3转化酶识别底物C3以及fH,DAF和MCP的调节活性至关重要,所有这些都对治疗发展产生了影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号